Mativ's New Blueprint: From Cost Cutting to Growth, Anchored by an Aerospace Win
Mativ Holdings (MATV) reported its first-quarter 2026 earnings on May 7, and the message was clear: this is no longer a story of survival, but of strategic transformation. The company, a specialty chemicals and materials player, has been in a multi-year drawdown (stock -80% from its 2013 peak), yet the recent tape shows a sharp +46.5% pop in the last 90 days, with a +56% surge in the final four weeks. That momentum mirrors the tone of the call—management is pivoting from deleveraging and cost discipline to growth, and it's starting to show in the numbers.
A Quarter of Inflection
The headline was solid: net sales of $480M were nearly flat, but adjusted EBITDA jumped 28% to $47.5M, with margins up 220 basis points to 9.9%—the strongest Q1 since the merger. “This represents our strongest Q1 margin performance since the mid-2022 merger.” — Scott Minder, Chief Financial Officer · 2026-05-07 free cash flow also improved by >$22M year-over-year to a use of $7M, an unusually strong seasonal performance. Underlying that is a relentless focus on pricing actions—the company's most-spiked keyword in the quarter—as management works to offset rising input costs.
What's notable is the formalization of a strategic blueprint that moves beyond cost-cutting. Shruti Singhal, CEO, described a vision to "be the preferred global partner for customers" and to accelerate growth via high-return markets. The single most concrete proof point: a sizable new commitment for specialty films from a new aerospace customer. “We recently earned a sizable new commitment for specialty films from a new aerospace customer. This is another proof point for our strategy of applying existing process capabilities and product knowledge to grow in adjacent markets.” — Shruti Singhal, President and Chief Executive Officer · 2026-05-07 The relationship commences in Q2, with shipments ramping later, meaning the benefits will flow through the P&L in subsequent quarters.
Our commercial agility, value-based pricing strategies, and rigorous operational discipline give us the confidence that we can successfully navigate this volatility and continue to deliver consistent results in times of uncertainty.
Pricing Power and Inflation Management
Input cost inflation—driven by the Middle East conflict—has accelerated from an initial $20–25M to a revised $40–50M for 2026. Management has responded with a second round of pricing actions across all product categories. CFO Scott Minder reiterated a commitment to fully offset the inflation: “we expect our pricing actions fully offset the $40 million to $50 million of forecasted input cost inflation in 2026.” — Scott Minder, Chief Financial Officer · 2026-05-07 This is a recurring theme; in the prior quarter's call, the same discipline was on display. “The team did a really good job in 2025. We generated record free cash flow of $94 million.” — Scott Minder, Chief Financial Officer · 2026-02-19 The continuity is reassuring—pricing power is a core competency, not a one-off.
Balance Sheet Reset
The April refinancing was a major de-risking event: the company simplified from 15 to 8 bank lenders, extended maturities (revolver and Term Loan A to 2031, Term Loan B to 2033), and eliminated the delayed draw term loan. Net debt sits at $954M, with net leverage at 4.1x, down slightly from year-end.
Headwinds and the Quarter Ahead
Not everything is rosy. Healthcare volumes were weak due to customer destocking and a temporary outage at the Knoxville facility. Release liner and labels remain soft. Management expects Q2 adjusted EBITDA to be down mid-single-digit % year-over-year—a cautious tone despite the record Q1. Yet the diversified portfolio is providing offsets: European filtration is strong, and the company's commercial pipeline has materially expanded. As Shruti noted, the strategic review continues, but the focus has shifted to winning in high-growth adjacencies.
What changed? The company has moved from a reactive cost-cutter to a proactive growth-builder. The aerospace win and the strategic blueprint are company-unique keywords—not sector boilerplate. The stock's recent surge suggests investors are buying the narrative. The fundamentals support it: gross margin up 2.7pp YoY, operating margin improving, and free cash flow margin on the mend.